We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Proteinuria After Acute Kidney Injury Predicts Development of Progressive Disease

By LabMedica International staff writers
Posted on 03 Feb 2020
A report has suggested that testing recently hospitalized kidney patients for proteinuria could be a way to identify those at higher risk for developing progressive kidney disease, which could require dialysis or surgery.

Clinicians agree that among patients who had acute kidney injury (AKI) during hospitalization, there is a need to improve risk prediction so that those at highest risk for subsequent loss of kidney function are identified for appropriate follow-up. More...


To this end, investigators at the University of California, San Francisco (USA) and colleagues at several other institutions worked with participants in The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study. This was a multicenter prospective cohort study including four clinical centers in North America that included 1538 patients enrolled three months after hospital discharge between December 2009 and February 2015. Of the 1538 participants, 769 (50%) had AKI during hospitalization.

To detect proteinuria, the investigators measured urine albumin-to-creatinine ratio (ACR) three months after hospital discharge. The mean age of the patients was 65 years, and the median urine ACR was 15 milligrams per gram. Overall, 547 (37%) of the participants were women and 195 (13%) were black.

Results revealed that after a median follow-up of 4.7 years, 138 (9%) participants had kidney disease progression. Higher post-AKI urine ACR level was associated with increased risk of kidney disease progression, and urine ACR measurement was a strong discriminator for future kidney disease progression. The performance of urine ACR was stronger in patients who had had AKI than in those who had not.

"There should be much more emphasis on the testing of proteinuria after AKI to identify high-risk patients," said first author Dr. Chi-yuan Hsu, professor of nephrology at the University of California, San Francisco. "This simple test carries important prognostic information not conveyed by serum creatinine. Too many providers rely on serum creatinine alone to assess the health of the kidneys, but they should not be falsely assured by the latter. Having a more complete picture of kidney health is necessary for proper clinical decision-making."

"Most patients with acute kidney injury are unaware of their condition, lack understanding of its natural history or predisposing factors, and desire more information," said Dr. Hsu. "However, few discharge communications currently provided to these patients explain the condition or provide recommendations for care, which is needed throughout the care continuum."

The AKI study was published in the January 27, 2020, online edition of the journal JAMA Internal Medicine.

Related Links:
University of California, San Francisco


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.